JP2602387B2 - Lipase inhibitor - Google Patents
Lipase inhibitorInfo
- Publication number
- JP2602387B2 JP2602387B2 JP4053558A JP5355892A JP2602387B2 JP 2602387 B2 JP2602387 B2 JP 2602387B2 JP 4053558 A JP4053558 A JP 4053558A JP 5355892 A JP5355892 A JP 5355892A JP 2602387 B2 JP2602387 B2 JP 2602387B2
- Authority
- JP
- Japan
- Prior art keywords
- lipase
- extract
- tea
- present
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940086609 Lipase inhibitor Drugs 0.000 title claims description 10
- 239000000284 extract Substances 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000012454 non-polar solvent Substances 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- 241000202755 Areca Species 0.000 claims 1
- 241000218657 Picea Species 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 description 17
- 239000004367 Lipase Substances 0.000 description 17
- 102000004882 Lipase Human genes 0.000 description 17
- 229940040461 lipase Drugs 0.000 description 17
- 235000019421 lipase Nutrition 0.000 description 17
- 235000013305 food Nutrition 0.000 description 12
- 244000269722 Thea sinensis Species 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 10
- 235000020824 obesity Nutrition 0.000 description 10
- 230000002265 prevention Effects 0.000 description 9
- 235000013616 tea Nutrition 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 102000019280 Pancreatic lipases Human genes 0.000 description 7
- 108050006759 Pancreatic lipases Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 229940116369 pancreatic lipase Drugs 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 235000019626 lipase activity Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 244000080767 Areca catechu Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- JEDBBFHVVHKMKS-UHFFFAOYSA-N 5,7-dimethoxy-8-(3-methylbut-2-enoyl)chromen-2-one Chemical compound C1=CC(=O)OC2=C(C(=O)C=C(C)C)C(OC)=CC(OC)=C21 JEDBBFHVVHKMKS-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 235000006226 Areca catechu Nutrition 0.000 description 2
- -1 Arecadin Chemical compound 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 235000003325 Ilex Nutrition 0.000 description 2
- 241000209035 Ilex Species 0.000 description 2
- 241001358279 Malaya Species 0.000 description 2
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NYRXUBDGDSRBGB-UHFFFAOYSA-N Obtusifolin Chemical compound O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(C)C(O)=C2OC NYRXUBDGDSRBGB-UHFFFAOYSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- QTDZOWFRBNTPQR-UHFFFAOYSA-N guvacine Chemical compound OC(=O)C1=CCCNC1 QTDZOWFRBNTPQR-UHFFFAOYSA-N 0.000 description 2
- JHGVLAHJJNKSAW-UHFFFAOYSA-N herniarin Natural products C1CC(=O)OC2=CC(OC)=CC=C21 JHGVLAHJJNKSAW-UHFFFAOYSA-N 0.000 description 2
- LIIALPBMIOVAHH-UHFFFAOYSA-N herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- ZLQJVGSVJRBUNL-UHFFFAOYSA-N methylumbelliferone Natural products C1=C(O)C=C2OC(=O)C(C)=CC2=C1 ZLQJVGSVJRBUNL-UHFFFAOYSA-N 0.000 description 2
- 229940116852 myricetin Drugs 0.000 description 2
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 2
- 235000007743 myricetin Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- JZYCZVLVWUCHTP-UHFFFAOYSA-N 7-methoxy-2-oxochromene-6-carbaldehyde Chemical compound O1C(=O)C=CC2=C1C=C(OC)C(C=O)=C2 JZYCZVLVWUCHTP-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 235000014552 Cassia tora Nutrition 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 244000062241 Kaempferia galanga Species 0.000 description 1
- 235000013421 Kaempferia galanga Nutrition 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- 244000132436 Myrica rubra Species 0.000 description 1
- 235000014631 Myrica rubra Nutrition 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- ZCHGCYXNSBHAEG-UHFFFAOYSA-N Obtusifolin Natural products COc1ccc2C=C(C(=O)Oc2c1C=CC(=C)C)C(C)(C)C=C ZCHGCYXNSBHAEG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 240000001462 Pleurotus ostreatus Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000276699 Seriola Species 0.000 description 1
- 244000061457 Solanum nigrum Species 0.000 description 1
- 241000512294 Thais Species 0.000 description 1
- 235000002096 Vicia faba var. equina Nutrition 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000002026 carminative effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- ZEGGZNOPAPRAIG-UHFFFAOYSA-N crenulatin Natural products C=CC(C)(C)OC1OC(CO)C(O)C(O)C1O ZEGGZNOPAPRAIG-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000005489 dwarf bean Nutrition 0.000 description 1
- 244000013123 dwarf bean Species 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000020958 lipid digestion Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 239000002420 orchard Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 108010079522 solysime Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明はリパーゼ阻害剤に関し、
更に詳しくは、生体内で脂質の消化吸収をにない肥満症
の鍵を握る膵リパーゼを有効に阻害して肥満の抑制や予
防に寄与し得ると共に、リパーゼに起因する食品等の劣
化や悪臭発生の防止に利用することができる安全性の高
いリパーゼ阻害物質に関する。The present invention relates to lipase inhibitors,
More specifically, it effectively inhibits pancreatic lipase, which is the key to obesity, which does not have lipid digestion and absorption in vivo, and can contribute to the suppression and prevention of obesity, and also causes degradation of foods and odor caused by lipase The present invention relates to a highly safe lipase inhibitor that can be used for preventing lipase.
【0002】[0002]
【従来の技術】ヒトにおいてリパーゼ(膵リパーゼ)は
脂質の消化吸収のキー酵素として働いており、膵リパー
ゼを阻害して肥満症を抑制したり予防する薬剤の開発が
従来より試みられている。例えば、特開昭55−981
14号に記載された抗肥満及びトリグリセリド減少剤、
特開昭61−152663号に記載されたオキセタノン
類および特開平1−102022号に記載された肥満予
防剤等を例示することができる。2. Description of the Related Art Lipase (pancreatic lipase) functions as a key enzyme in the digestion and absorption of lipids in humans, and attempts have been made to develop drugs that inhibit pancreatic lipase to suppress or prevent obesity. For example, JP-A-55-981
An antiobesity and triglyceride reducing agent described in No. 14,
Oxetanones described in JP-A-61-252663 and obesity preventive agents described in JP-A-1-102022 can be exemplified.
【0003】また、同様の目的で、穀類、豆類から分離
した阻害物質を添加した飲食品(特開昭64−3426
4号)や脂肪に富んだ種子からの阻害物質の抽出法(特
開昭49−41580号)等が開示されている。[0003] For the same purpose, foods and drinks to which an inhibitory substance isolated from cereals and beans are added (Japanese Patent Application Laid-Open No. 64-3426).
No. 4) and a method for extracting inhibitory substances from fat-rich seeds (JP-A-49-41580).
【0004】一方、飼い葉(Fodder plan
t)のタンニン類がリパーゼを阻害することや(Bri
tish J. Nutrition,60,275
(1988))、豆(Field bean)の抽出物
(タンニン)がリパーゼを阻害することが知られている
(J. Sci. Food Agric.,30,4
58(1979))。また大豆や穀類、大根種子からの
蛋白質がこれを阻害することが報告されている(Agr
ic. Biol. Chem.,37,1225,
(1973)、Nurt. Rep. Int.,3
2,1107(1985)、日本食品工業会誌、35,
430(1988))。更にヘミセルロースや小麦ふす
ま等(J. Food Sci.,49,956(19
84)、Am.J.Clin. Nutr.,42,6
29(1985))、大豆種子のフォスファチジルコリ
ン(明治大学農学部研究報告、73,9(198
6))、ミオイノシトール(J. Food Sc
i.,53,250(1988))等によるリパーゼ阻
害に関する報告がある。On the other hand, forage (Fodder plan)
t) that tannins inhibit lipase and (Bri)
tissue J. Nutrition, 60, 275
(1988)), and an extract (tannin) of beans (Field bean) is known to inhibit lipase (J. Sci. Food Agric., 30, 4).
58 (1979)). It has also been reported that proteins from soybeans, cereals and radish seeds inhibit this (Agr).
ic. Biol. Chem. , 37,1225,
(1973), Nurt. Rep. Int. , 3
2, 1107 (1985), Journal of the Japan Food Industry Association, 35,
430 (1988)). Further, hemicellulose, wheat bran, and the like (J. Food Sci., 49, 956 (19)
84), Am. J. Clin. Nutr. , 42,6
29 (1985)), phosphatidylcholine in soybean seeds (Research Report of the Faculty of Agriculture, Meiji University, 73, 9 (198)
6)), myo-inositol (J. Food Sc)
i. , 53, 250 (1988)) and the like.
【0005】生薬類については微生物リパーゼに対する
ものとして、シャクヤク、オオレン、オオバク、ボタン
ビ、ゲンノショウコ、茶等の14種の生薬の抽出物が開
示されている(特開昭64−90131号)。また微生
物リパーゼに対するものとして25種の生薬について阻
害作用を調べた結果が報告されている(明治大学農学部
研究報告、69,15(1985))。[0005] Regarding crude drugs, extracts of 14 kinds of crude drugs such as peonies, oren, psyllium, buttonbi, genoshoko, tea and the like are disclosed as microorganisms against lipase (Japanese Patent Application Laid-Open No. 64-90131). In addition, the result of examining the inhibitory effect of 25 kinds of crude drugs against microbial lipase has been reported (Meiji University, Faculty of Agriculture, Research Report, 69, 15 (1985)).
【0006】更に最近では、ピーマン、かぼちゃ、しめ
じ、まいたけ、ひじき、緑茶、紅茶、ウーロン茶の水抽
出物からなるリパーゼ阻害剤(特開平3−219872
号)や、緑茶中の主要な成分であるエピガロカテキンガ
レートを配合することを特徴とする脂質吸収抑制食品
(特開平3−228664号)が開示されている。More recently, a lipase inhibitor comprising an aqueous extract of peppers, pumpkins, shimeji, maitake, hijiki, green tea, black tea, and oolong tea (Japanese Patent Laid-Open No. 3-219873).
No. 3) and a lipid absorption-suppressed food (JP-A-3-228664) characterized by incorporating epigallocatechin gallate, which is a main component in green tea.
【0007】[0007]
【発明が解決しようとする課題】天然の生薬は安全性が
高く、種々の薬効があることが知られている。これら多
くの生薬類の抽出物より、リパーゼ活性を阻害するもの
を探索し、数種の生薬抽出物に著しく高い阻害作用があ
ることをこの度突き止めた。It is known that natural crude drugs are highly safe and have various medicinal effects. From the extracts of these many crude drugs, those that inhibit lipase activity were searched, and this time, it was found that several kinds of crude drug extracts had a remarkably high inhibitory effect.
【0008】本発明は、生体内で脂質の消化吸収を司り
肥満症の鍵を握る膵リパーゼに対して著しく高い阻害作
用を示し、これを阻害して肥満の抑制や予防に寄与し得
ると共に、リパーゼに起因する食品等の劣化や悪臭発生
の防止に利用することができる安全性の高いリパーゼ阻
害剤を提供することを目的とする。[0008] The present invention has a remarkably high inhibitory effect on pancreatic lipase, which controls the digestion and absorption of lipids in vivo and is a key to obesity, and can inhibit this to contribute to the suppression and prevention of obesity. An object of the present invention is to provide a highly safe lipase inhibitor that can be used for preventing deterioration of foods and the like and odor generation due to lipase.
【0009】[0009]
【課題を解決するための手段】本発明によれば、ドッカ
ツ、リョウキョウ、ビンロウシ、ヨウバイヒ、サンペン
ズおよびケツメイシよりなる群から選択される一種以上
の生薬の極性もしくは非極性溶媒抽出エキスを有効成分
とすることを特徴とするリパーゼ阻害剤が提供される。According to the present invention, a polar or non-polar solvent extract of one or more crude drugs selected from the group consisting of Dokkatsu, Ryokyo, Acacia, L., Sempens and Katsumeishi is used as an active ingredient. A lipase inhibitor is provided.
【0010】ドッカツ(独活)は、Angelica
pubescens Maximowicz(シシウ
ド)の根であり、漢方では発汗、駆風、沈痛薬として風
邪を去り、浮腫を散らす効果があるとされている。根に
はGlabra−lactone、Angelical
(7−Methoxy−6−coumarinalde
hyde)が存在することが示されている。[0010] Dokkatsu (independent) is Angelica
It is the root of pubescens maximowicz (Shishuudo), and is said to be effective in Chinese medicine as a sweating, carminative, and painkiller to remove colds and spread edema. Glabra-lactone, Angelical on roots
(7-Methoxy-6-coumarinalde
hyde) is present.
【0011】リョウキョウ(良姜)は、ショウガ科コウ
リョウキョウ、Alpina officinarum
Hance(一般名galanga)の根茎をリョウ
キョウと呼ぶものである。[0011] Ryokyo (Ryokyo) is a ginger of the family Ginger, Alpina officinarum.
The rhizome of Hance (general name galanga) is called Ryokyo.
【0012】ビンロウシ(檳榔子)は、ヤシ科ビンロ
ウ、Areca Catechu L.の成熟した種子
であり、マラヤ、インドネシア、フィリピンが産地であ
る。Arecoline、Arecadin、Guva
cine等がその中に存在し、寄生虫除去、視力障害治
癒の効果があるとされる。マラヤ人、タイワン人はこれ
を咬む習慣がある。[0012] Betel nut (Acacia lutes) is a species of betel palm, Areca Cathu L. And grown in Malaya, Indonesia and the Philippines. Arecoline, Arecadin, Guva
Cine and the like are present therein, and are said to be effective in removing parasites and healing visual impairment. Malayas and Thais have the habit of biting this.
【0013】ヨウバイヒ(楊梅皮)は、ヤマモモ、My
rica rubra Siebold et Zuc
cariniの樹皮であり、九州各地に産する。タンニ
ン、Myricetin等が存在することが知られてい
る。漢方では下痢や打撲症、解毒の効があるとされる。
Myricetinには利尿効果がある。[0013] Youbaihi (Yangmei skin) is, bayberry, My
rica rubra Siebold et Zuc
It is the bark of carini and is found throughout Kyushu. It is known that tannin, Myricetin and the like exist. In Kampo, it is said to be effective for diarrhea, bruises and detoxification.
Myricetin has a diuretic effect.
【0014】サンペンズ(山扁豆)は、カワラケツメ
イ、Cassia nomame Honda (Ca
ssia mimosoides L. var. n
omame Makino)の帯果期の茎葉を乾燥した
ものであり、全国各地に産する。浜茶、マメ茶として茶
がわりに飲用される。漢方では利尿や緩下効果があると
される。多量の飲用でも副作用はないとされる。[0014] Sampens (Yamabushi) is a Japanese name for "Karaoketsumei" , Cassia noname Honda ( Ca
ssia mimosoides L. var. n
Oma Makino) is a dried version of the foliage at the orchard stage, and is produced throughout the country. Tea is used as beach tea and bean tea instead. It is said that Kampo has diuretic and laxative effects. It is said that there is no side effect even with heavy drinking.
【0015】ケツメイシ(決明子)は、エビスグサ(C
assia obtusifolia L.)の成熟し
た種子であり、熱帯アジアの原産である。漢方では緩下
作用、強壮、視力改善効果があるとされる。成分にはE
modin、Obtusifolin等が知られてい
る。ハブ茶と呼ばれ茶がわりに飲用される。[0015] Ketsumeishi (cassia seed) is, sicklepod (C
assia obtusifolia L. ) Is a mature seed and is native to tropical Asia. It is said that Chinese medicine has a laxative effect, tonicity, and visual acuity improving effect. The component is E
modin, Obtusifolin and the like are known. It is called hub tea and tea is consumed instead.
【0016】これらの生薬から有効成分を抽出するに際
し、抽出溶媒は水(もしくは緩衝液)または有機溶媒
(例えばヘキサン、エーテル、クロロホルム、ベンゼ
ン、トルエン、酢酸エチル、テトラヒドロフラン、ブタ
ノール、プロパノール、アセトン、エタノール、メタノ
ール等)より適切なものを一種以上選択することができ
るが、ドッカツ、リョウキョウ、ビンロウシ、ヨウバイ
ヒについては、水もしくは緩衝液を用いることが望まし
い。緩衝液としては、pH3.0〜10.0の範囲で好
適に使用することができるドッカツ、ビンロウシおよび
ヨウバイヒ等を例示することができる。一方、サンペン
ズ、ケツメイシについてはTHF等の有機溶媒を用いる
ことが好ましい。In extracting the active ingredient from these crude drugs, the extraction solvent is water (or buffer) or an organic solvent (eg, hexane, ether, chloroform, benzene, toluene, ethyl acetate, tetrahydrofuran, butanol, propanol, acetone, ethanol). , Methanol, etc.), one or more of which can be selected, but it is desirable to use water or a buffer for Dokkatsu, Ryokyo, Acacia, and Ilex. Examples of the buffer include docker, areca and oleax which can be suitably used in the pH range of 3.0 to 10.0. On the other hand, it is preferable to use an organic solvent such as THF for Sampens and Katsumeishi.
【0017】前記生薬抽出エキスは適切な溶媒で希釈し
たり、あるいは濃縮して使用することができる。また吸
引や凍結乾燥等の操作によりペースト状あるいは粉末状
にして使用することができる。またこれらは食品等に予
め混合することもでき、また適宜製剤化してリパーゼ阻
害剤として使用することができる。The crude drug extract can be diluted with an appropriate solvent or concentrated. Further, it can be used in the form of paste or powder by operations such as suction and freeze-drying. These can be mixed in advance with foods or the like, or can be formulated as appropriate and used as a lipase inhibitor.
【0018】[0018]
【作用】本発明は、ドッカツ、リョウキョウ、ビンロウ
シ、ヨウバイヒ、サンペンズおよびケツメイシの6種の
生薬よりなる群から選択される一種以上の生薬の極性も
しくは非極性溶媒抽出エキスを有効成分とするリパーゼ
阻害剤に関する。The present invention relates to a lipase inhibitor comprising, as an active ingredient, a polar or non-polar solvent extract of one or more crude drugs selected from the group consisting of six crude drugs of Dokkatsu, Ryokyo, Amberjack, Ilex, Sampens and Ketmeishi. Agent.
【0019】これらの抽出物は、従来よりリパーゼ阻害
作用が高いとされる茶抽出物よりも効果が高く、これら
の抽出物は合成の物質ではなく天然の植物由来のもので
あるため安全性の高い阻害物質を提供することができ
る。These extracts are more effective than tea extracts, which are conventionally considered to have a high lipase inhibitory action. These extracts are not synthetic substances but derived from natural plants, so that their safety is high. High inhibitors can be provided.
【0020】またこれらの抽出物は油脂の消化吸収の阻
害に基く肥満予防や、リパーゼに起因する疾患の予防、
防止に利用することができる。更にこれらの抽出物はリ
パーゼに起因する食品等の劣化、悪臭の発生の防止に利
用することができる。These extracts can be used to prevent obesity by inhibiting digestion and absorption of fats and oils, to prevent diseases caused by lipase,
Can be used for prevention. Further, these extracts can be used to prevent deterioration of foods and the like and odor caused by lipase.
【0021】[0021]
【発明の効果】本発明によれば、生体内で脂質の消化吸
収を司り肥満症の鍵を握る膵リパーゼに対して著しく高
い阻害作用を示し、これを阻害して肥満の抑制や予防に
寄与し得ると共に、リパーゼに起因する食品等の劣化や
悪臭発生の防止に利用することができる安全性の高いリ
パーゼ阻害剤が提供される。Industrial Applicability According to the present invention, the present invention has a remarkably high inhibitory effect on pancreatic lipase, which controls the digestion and absorption of lipids in vivo and is a key to obesity, and inhibits this to contribute to the suppression and prevention of obesity. The present invention provides a highly safe lipase inhibitor which can be used for preventing deterioration of foods and the like and malodor caused by lipase.
【0022】本発明のリパーゼ阻害剤はリパーゼの活性
を強力かつ有効に抑制し、合成物質と異なり天然物由来
であるためより安全性が高い。The lipase inhibitor of the present invention strongly and effectively suppresses the activity of lipase, and is safer because it is derived from natural products unlike synthetic substances.
【0023】また本発明品はリパーゼ阻害による肥満防
止や、リパーゼが原因で起こる種々の疾患の予防、防止
に利用することができると共に、リパーゼが原因とされ
る油脂の分解に伴う悪臭の防止等、食品等の劣化防止等
に応用することができる。The product of the present invention can be used for prevention of obesity by lipase inhibition, prevention and prevention of various diseases caused by lipase, and prevention of malodor accompanying degradation of oils and fats caused by lipase. It can be applied to the prevention of deterioration of foods and the like.
【0024】[0024]
【実施例】以下に実施例により本発明を更に詳細に説明
するが、本発明は以下の実施例にのみ限定されるもので
はない。The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to the following examples.
【0025】実施例1−1(リパーゼ活性測定法) リパーゼ活性の測定は、基質に蛍光性の4−メチルウン
ベリフェロンのオレイン酸エステル(4−MUO)を使
用し、反応によって生成した4−メチルウンベリフェロ
ンの蛍光を測定することによって行った。 Example 1-1 (Measuring method of lipase activity ) The lipase activity was measured by using oleic acid ester of 4-methylumbelliferone (4-MUO) as a substrate and producing 4-methylumbelliferone by reaction. This was done by measuring the fluorescence of methylumbelliferone.
【0026】小試験官に基質である4−MUO懸濁液1
00μl、ブタ膵リパーゼ(Sigma社製)溶液50
μl、緩衝液50μlを採り、最終的に4−MUO0.
05mM、ブタ膵リパーゼ2.2μg、Mcllvai
ne緩衝液(pH7.4)の条件で37℃で20分間反
応させた。0.1N塩酸1mlを添加して反応を停止さ
せ、0.1Mクエン酸ナトリウムを2ml添加して溶液
のpHを4.3付近とした後、反応によって生成した4
−メチルウンベリフェロンの蛍光(励起波長320n
m、蛍光波長450nm)を蛍光光度計により測定し
た。The small examiner asked the substrate 4-MUO suspension 1
00 μl, porcine pancreatic lipase (manufactured by Sigma) solution 50
μl and 50 μl of buffer solution, and finally 4-MUO.
05 mM, porcine pancreatic lipase 2.2 μg, Mcllvai
The reaction was carried out at 37 ° C. for 20 minutes under the conditions of a ne buffer (pH 7.4). The reaction was stopped by adding 1 ml of 0.1N hydrochloric acid, and the pH of the solution was adjusted to around 4.3 by adding 2 ml of 0.1 M sodium citrate.
-Fluorescence of methyl umbelliferone (excitation wavelength 320 n
m, fluorescence wavelength 450 nm) was measured with a fluorometer.
【0027】実施例1−2(抽出エキスの調製) 乾燥した生薬を粉砕し、粉砕物に対して50倍量のMc
llvaine緩衝液を加え、ホモジナイザーにてホモ
ジナイズ後、一日浸漬して抽出した。これをろ過し、そ
のろ液を抽出エキスとした。また生薬によっては以下の
ような方法にて抽出した。粉砕物に対して5倍量のヘキ
サンにより一日抽出脱脂し、この抽出残渣を吸引乾燥
後、5倍量のテトラヒドロフランを加えて一日抽出後、
ろ過し、このろ液を抽出エキスとした。 Example 1-2 (Preparation of Extract Extract) Dried crude drug was pulverized, and a 50-fold amount of Mc with respect to the pulverized product was used.
After adding an llvaine buffer, homogenizing with a homogenizer and immersing for 1 day for extraction. This was filtered, and the filtrate was used as an extract. Some crude drugs were extracted by the following method. The crushed product is extracted and defatted for one day with 5 times the amount of hexane, and the extraction residue is suction-dried. After adding 5 times the amount of tetrahydrofuran and extracting for 1 day,
After filtration, the filtrate was used as an extract.
【0028】実施例1−3(抽出エキスの効果の測定) リパーゼ活性に及ぼす抽出エキスの阻害効果の測定は、
前記実施例に示したリパーゼ活性の測定系に抽出エキス
を添加して反応させ、活性に対する影響を調べることに
より行った。 Example 1-3 (Measurement of Effect of Extract Extract ) The measurement of the inhibitory effect of the extract on lipase activity was carried out as follows.
Extraction extract was added to the lipase activity measurement system shown in the above Examples and reacted to examine the effect on the activity.
【0029】Mcllvaine緩衝液にて抽出したエ
キスに対しては、反応系の緩衝液50μlの代りにエキ
ス50μlを添加し、THFにて抽出したエキスについ
ては5μlを添加した。なお、エキスと同じ溶媒を同量
添加したものを対照とし、エキス添加時の活性は対照に
対する相対活性として示した。To the extract extracted with Mcllvaine buffer, 50 μl of the extract was added instead of 50 μl of the reaction system buffer, and 5 μl of the extract extracted with THF was added. In addition, the thing which added the same solvent and the same solvent as an extract was set as control, and the activity at the time of adding an extract was shown as relative activity with respect to a control.
【0030】実施例1−4(各種抽出エキスの比較) 前記実施例に従い、各種の生薬の抽出エキスのリパーゼ
活性に及ぼす影響を調べた。その結果を表1に示す。 Examples 1-4 (Comparison of Various Extracts) The effects of various crude drugs on the lipase activity were examined in accordance with the above Examples. Table 1 shows the results.
【0031】[0031]
【表1】 [Table 1]
【0032】茶抽出エキスについてはリパーゼ阻害作用
が高いことが知られているが、表1から明らかなよう
に、これらの生薬抽出エキスは茶抽出エキスよりも明ら
かに高いリパーゼ阻害作用を有していることが判った。It is known that tea extract has a high lipase inhibitory activity, but as is clear from Table 1, these crude drug extracts have a clearly higher lipase inhibitory activity than tea extract. I found out.
Claims (1)
ヨウバイヒ、サンペンズおよびケツメイシよりなる群か
ら選択される一種以上の生薬の極性もしくは非極性溶媒
抽出エキスを有効成分とすることを特徴とするリパーゼ
阻害剤。1. Dokatsu, Ryokyo, Areca,
A lipase inhibitor comprising, as an active ingredient, a polar or non-polar solvent extract of one or more crude drugs selected from the group consisting of Spruce, Sampen's and Katsumeishi.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4053558A JP2602387B2 (en) | 1992-03-12 | 1992-03-12 | Lipase inhibitor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4053558A JP2602387B2 (en) | 1992-03-12 | 1992-03-12 | Lipase inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05255100A JPH05255100A (en) | 1993-10-05 |
JP2602387B2 true JP2602387B2 (en) | 1997-04-23 |
Family
ID=12946144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4053558A Expired - Fee Related JP2602387B2 (en) | 1992-03-12 | 1992-03-12 | Lipase inhibitor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2602387B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004168767A (en) * | 2002-10-30 | 2004-06-17 | Taisho Pharmaceut Co Ltd | α-glucosidase inhibitor |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2618202B2 (en) * | 1994-06-23 | 1997-06-11 | 株式会社ロッテ | Blood lipid lowering agent and food and drink containing it |
DE19741397A1 (en) * | 1997-09-19 | 1999-03-25 | Henkel Kgaa | Organic extract from Cassia inermis or Lawsonia auriculata for use in cosmetics |
JP5110673B2 (en) * | 2001-07-10 | 2012-12-26 | 丸善製薬株式会社 | Lipase inhibitor |
JP2005239659A (en) * | 2004-02-27 | 2005-09-08 | Nicca Chemical Co Ltd | Precursor lipocyte differentiation inhibitor |
WO2007097478A1 (en) * | 2006-02-21 | 2007-08-30 | Dongguk University Industry-Academic Cooperation Foundation | Composition for anti-arteriosclerosis containing aralia continentalis extracts |
PT1923067T (en) * | 2006-11-20 | 2016-07-14 | S I I T S R L -Servizio Int Imballaggi Termosaldanti | Compositions containing phaseolus vulgaris extract and alpinia officinarum extract for the prevention and treatment of obesity and type ii diabetes |
JP5596654B2 (en) * | 2011-10-14 | 2014-09-24 | 丸善製薬株式会社 | Lipase inhibitor |
JP2013079276A (en) * | 2013-01-04 | 2013-05-02 | Lotte Co Ltd | Methioninase inhibitor, and oral cavity composition and food and drink, containing the same |
-
1992
- 1992-03-12 JP JP4053558A patent/JP2602387B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004168767A (en) * | 2002-10-30 | 2004-06-17 | Taisho Pharmaceut Co Ltd | α-glucosidase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
JPH05255100A (en) | 1993-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Khazaei et al. | A review on the mechanisms of the effect of silymarin in milk thistle (Silybum marianum) on some laboratory animals | |
JP5875896B2 (en) | Bioactive compositions derived from camellia plants and processes for producing and using them | |
Ahmad et al. | Phytochemical composition and pharmacological prospectus of Ficus bengalensis Linn.(Moraceae)-A | |
JP2598873B2 (en) | Lipase inhibitor and food and drink to which it is added | |
US5629338A (en) | Tannins and lipase inhibitors containing the same as active ingredients | |
JP2602387B2 (en) | Lipase inhibitor | |
Saryono et al. | Anti-inflammatory effect of date seeds (Phoenix dactylifera L) on carrageenan-induced edema in rats | |
KR101624713B1 (en) | Ecklonia cava extract for decreasing body weight and manufacturing method thereof | |
Gupta et al. | Babool (Acacia nilotica) | |
KR101252023B1 (en) | Vapor fraction from seeds of glycine max(l.) merr. and composition thereof | |
Bashir et al. | Coriander seeds: ethno-medicinal, phytochemical and pharmacological profile | |
KR100948281B1 (en) | The method of preparing the functional food for diet using extractive extracted from madicin-materials of plants | |
Matta et al. | Phytopharmaceutical potentials of Prosopis laevigata, Symplocos cochinchinensis and Nymphaea alba: a review | |
Aminabee et al. | Evaluation of Analgesic Activity of Ficus Palmata: Evaluation of Analgesic activity of Ficus palmata | |
Putra et al. | Benefits total phenolic and flavonoid content of Portulaca oleracea as Antioxidant and Antidiabetic: A Review | |
Silalahi | Morinda citrifolia: Bioactivity and utilization as traditional medicine and food for the community | |
Haroon | Effect of some macrophytes extracts on growth of Aspergillus parasiticus | |
Nwachukwu et al. | Influence of extraction methods on the hepatotoxicity of Azadirachta indica bark extract on albino rats | |
Wudali et al. | Bioactive phytochemicals from date palm (Phoenix dactylifera L.) seed oil processing by-products | |
Swathi et al. | Phytochemistry and Pharmacological Bio-Activities of Lannea coromandelica: A Review | |
KR101332531B1 (en) | Composition for preventing and/or treating itching containing component originating in the bark of tree belonging to the genus acacia | |
Alsamri et al. | Pharmacological and Antioxidant Activities of Rhus coriaria L.(Sumac). Antioxidants 2021, 10, 73 | |
Bisong et al. | Effects of aqueous leaf extracts of Murraya koenigii on learning and memory in mice | |
KAKATUM et al. | Biological activities of Butea monosperma (Lam.) Taub. flowers on skin care cosmetics. | |
Tohame et al. | Modulation of aflatoxins toxicity in rats by ethanolic pomegranate peel (Punica granatum. L) extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 19961126 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090129 Year of fee payment: 12 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090129 Year of fee payment: 12 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090129 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120129 Year of fee payment: 15 |
|
LAPS | Cancellation because of no payment of annual fees |